Fairfax employs a clever M&A strategy called the "cannibal buy-up." When an asset is too large to acquire outright, they partner with another firm. Later, when financially stronger, they use their capital to buy out the partner's stake, allowing them to gain 100% control of a valuable asset over time.

Instead of direct stock purchases during the COVID-19 crash, Fairfax used total return swaps on its own shares. This derivative strategy provided leveraged exposure to the stock's recovery, netting ~$2 billion in cash which was then deployed for even more repurchases at depressed prices.

The company's Total Return Swaps (TRS) are not just a speculative bet but a strategic tool. They function as a deferred buyback, allowing Fairfax to lock in a price while using the capital elsewhere until they formally close the swap and take delivery of the shares.

Companies termed "share cannibals" aggressively repurchase their own shares, especially when undervalued. This capital allocation strategy is often superior to dividends because it transfers value from sellers to long-term shareholders and acts as a high-return, low-risk investment in the company's own business.

Fairfax follows a clear capital allocation framework. They prioritize open market buybacks when the stock is below 1.5 times price-to-book. Above that multiple, they shift capital towards closing out their Total Return Swaps, providing a predictable approach for investors.

Fairfax executed a brilliant capital allocation move by selling a 10% stake in its subsidiary, Odyssey, to pension funds for 1.7 times its book value. They then used the billion-dollar proceeds to buy back their own undervalued parent company stock, which was trading at a discount of 0.9x book value.

When a company's stock trades at a significant discount to tangible assets, the market signals that every new dollar invested is immediately devalued. The correct capital allocation is returning capital to shareholders via buybacks or dividends, not pursuing growth projects that the market refuses to credit.

Fairfax targets well-run insurers that invest their float conservatively for low returns (e.g., 4%). By applying its superior investment arm to boost the float's return (e.g., to 7%), it dramatically increases the acquired company's ROE without altering core underwriting operations.

Instead of complaining that its stock trades at a steep discount to its net asset value (NAV), Exor's management pragmatically views this as a chance to invest in themselves. They trimmed their highly appreciated Ferrari stake specifically to fund share buybacks at this significant discount.